Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

Tobramycin Inhalation Powder; Placebo

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).

Номер протоколаCTBM100C2303
ФазаФаза III
Участников по плану — во всех странах исследования62
Сроки01.06.2009 — 01.05.2011
Начало: 1 июня 2009Окончание: 1 мая 2011
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00918957/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 6–21 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 62 чел. во всех странах исследования.
  • Плановая дата окончания (05.2011) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст6–21 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 23

Критерии включения

  • Written informed consent given by adults or by the parents/legal guardian in combination with the patient's assent, if capable of assenting, before any assessment was performed
  • Confirmed diagnosis of Cystic Fibrosis (CF) by the presence of one or more clinical features of CF in addition to:
  • a quantitative pilocarpine iontophoresis sweat chloride test of >60 mEq/L; or
  • identification of well-characterized disease-causing mutations in each CFTR gene; or
  • an abnormal nasal transepithelial potential difference characteristic of CF.
  • Forced Expiratory Volume in one second (FEV1) at screening must have been ≥25% and ≤80% of normal predicted values for age, sex, and height based on Knudson criteria
  • P. aeruginosa must have been present in a sputum/deep-throat cough swab culture (or bronchoalveolar lavage \[BAL\]) within 6 months prior to screening and in the sputum/deep-throat cough swab culture at the screening visit
  • Able to expectorate a sputum sample or provide a deep throat cough swab at screening
  • Able to comply with all protocol requirements
  • Use of an effective means of contraception in females of childbearing potential
  • Clinically stable in the opinion of the investigator to be treated according to this protocol

Критерии невключения

  • FEV1 at baseline (Visit 2) <25% or >80% of normal predicted values for age, sex, and height based on Knudson criteria, and/or FEV1 at baseline (Visit 2) deviated by ≥10% from the FEV1 measured at screening (Visit 1)
  • Any use of inhaled anti-pseudomonal antibiotics within 4 months prior to screening
  • Any use of systemic anti-pseudomonal antibiotics within 28 days prior to study drug administration
  • Serum creatinine 2 mg/dL or above, blood urea nitrogen (BUN) 40 mg/dL or above, or an abnormal urinalysis defined as 2+ or greater proteinuria
  • Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics
  • Signs and symptoms of acute pulmonary disease, e.g. pneumonia, pneumothorax
  • Administration of any investigational drug within 30 days prior to enrollment
  • Any previous exposure to tobramycin dry powder for inhalation (TIP)
  • Administration of loop diuretics within 7 days prior to study drug administration
  • Initiation of treatment with chronic macrolide therapy within 28 days prior to study drug administration
  • Initiation of treatment with dornase alfa within 28 days prior to study drug administration
  • Initiation of treatment with inhaled steroids (or increased dose) within 28 days prior to study drug administration
  • Initiation of treatment with inhaled hypertonic saline (HS) within 28 days prior to study drug administration
  • Personal history of abnormal hearing or family history of abnormal hearing other than typical hearing loss associated with the aging process
  • Known abnormal result from any audiology testing (defined as either a unilateral puretone audiometry test showing a threshold elevation >20 dB at any frequency across the frequency range 0.25 kHz to 8 kHz or the absence of emission at the evoked otoacoustic emission test)
  • History of sputum culture or throat swab (or BAL) culture yielding Burkholderia cepacia (B. cepacia) within 2 years prior to screening and/or sputum culture yielding B. cepacia at screening
  • Hemoptysis of more than 60 mL at any time within 30 days prior to study drug administration
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of evidence of local recurrence or metastases
  • Patients with clinically significant laboratory abnormalities (not associated with the study indication) at screening
  • Patients or caregivers with a history of noncompliance to medical regimens and patients or caregivers who are considered potentially unreliable
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential unless they used two reliable birth control methods
  • Other protocol-defined inclusion/exclusion criteria may apply

Источник: ClinicalTrials.gov, NCT00918957 · запись обновлена в реестре 3 октября 2012.

Дизайн и результаты

ДизайнРандомизированное, тройное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)62
Что измеряют — первичные конечные точки (3), вторичных — 9
  • Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29) — Baseline, Day 29
  • Pre-planned Sensitivity Analysis: Absolute Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent (%) Predicted to End of Dosing (Day 29) — Baseline, Day 29
  • Post-hoc: Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29) Without Outlier — Baseline, Day 29

Цель исследования

This study is designed to show how well tobramycin inhalation powder works and how safe it is when produced by a modified manufacturing process

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00918957 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.